Literature DB >> 29910175

TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models.

Gerónimo Fernández1, Ana Moraga2, María I Cuartero2, Alicia García-Culebras2, Carolina Peña-Martínez2, Jesús M Pradillo2, Macarena Hernández-Jiménez3, Silvia Sacristán4, M Irene Ayuso5, Rafael Gonzalo-Gobernado5, David Fernández-López2, M Elena Martín4, María A Moro2, Victor M González6, Ignacio Lizasoain7.   

Abstract

Since Toll-like receptor 4 (TLR4) mediates brain damage after stroke, development of TLR4 antagonists is a promising therapeutic strategy for this disease. Our aim was to generate TLR4-blocking DNA aptamers to be used for stroke treatment. From a random oligonucleotide pool, we identified two aptamers (ApTLR#1R, ApTLR#4F) with high affinity for human TLR4 by systematic evolution of ligands by exponential enrichment (SELEX). Optimized truncated forms (ApTLR#1RT, ApTLR#4FT) were obtained. Our data demonstrate specific binding of both aptamers to human TLR4 as well as a TLR4 antagonistic effect. ApTLR#4F and ApTLR#4FT showed a long-lasting protective effect against brain injury induced by middle cerebral artery occlusion (MCAO), an effect that was absent in TLR4-deficient mice. Similar effects were obtained in other MCAO models, including in rat. Additionally, efficacy of ApTLR#4FT in a model of brain ischemia-reperfusion in rat supports the use of this aptamer in patients undergoing artery recanalization induced by pharmacological or mechanical interventions. The absence of major toxicology aspects and the good safety profile of the aptamers further encourage their future clinical positioning for stroke therapy and possibly other diseases in which TLR4 plays a deleterious role.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SELEX; TLR4; aptamer; infarction; inflammation; ischemia; stroke; therapy

Mesh:

Substances:

Year:  2018        PMID: 29910175      PMCID: PMC6094477          DOI: 10.1016/j.ymthe.2018.05.019

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

Review 1.  DNA and RNA aptamers: from tools for basic research towards therapeutic applications.

Authors:  Henning Ulrich; Cleber A Trujillo; Arthur A Nery; Janaina M Alves; Paromita Majumder; Rodrigo R Resende; Antonio H Martins
Journal:  Comb Chem High Throughput Screen       Date:  2006-09       Impact factor: 1.339

2.  Toll-like receptor 4 antagonist attenuates intracerebral hemorrhage-induced brain injury.

Authors:  Yan-Chun Wang; Peng-Fei Wang; Huang Fang; Jing Chen; Xiao-Yi Xiong; Qing-Wu Yang
Journal:  Stroke       Date:  2013-07-09       Impact factor: 7.914

3.  Administration of transforming growth factor-alpha reduces infarct volume after transient focal cerebral ischemia in the rat.

Authors:  C Justicia; F J Pérez-Asensio; M C Burguete; J B Salom; A M Planas
Journal:  J Cereb Blood Flow Metab       Date:  2001-09       Impact factor: 6.200

Review 4.  Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns.

Authors:  Alejandro Bustamante; Alba Simats; Andrea Vilar-Bergua; Teresa García-Berrocoso; Joan Montaner
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

5.  A DNA aptamer population specifically detects Leishmania infantum H2A antigen.

Authors:  Edurne Ramos; David Piñeiro; Manuel Soto; Daniel R Abanades; M Elena Martín; Matilde Salinas; Víctor M González
Journal:  Lab Invest       Date:  2007-03-05       Impact factor: 5.662

6.  In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model.

Authors:  Christina C N Wu; Mojgan Sabet; Tomoko Hayashi; Rommel Tawatao; Joshua Fierer; Dennis A Carson; Donald G Guiney; Maripat Corr
Journal:  Cell Immunol       Date:  2008-05-20       Impact factor: 4.868

7.  Current views of toll-like receptor signaling pathways.

Authors:  Masahiro Yamamoto; Kiyoshi Takeda
Journal:  Gastroenterol Res Pract       Date:  2010-12-14       Impact factor: 2.260

8.  QGRS Mapper: a web-based server for predicting G-quadruplexes in nucleotide sequences.

Authors:  Oleg Kikin; Lawrence D'Antonio; Paramjeet S Bagga
Journal:  Nucleic Acids Res       Date:  2006-07-01       Impact factor: 16.971

9.  TAK-242, an antagonist for Toll-like receptor 4, protects against acute cerebral ischemia/reperfusion injury in mice.

Authors:  Fang Hua; Huiling Tang; Jun Wang; Megan C Prunty; Xiaodong Hua; Iqbal Sayeed; Donald G Stein
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

10.  Structural and affinity analyses of g-quadruplex DNA aptamers for camptothecin derivatives.

Authors:  Hiroto Fujita; Yuri Imaizumi; Yuuya Kasahara; Shunsuke Kitadume; Hiroaki Ozaki; Masayasu Kuwahara; Naoki Sugimoto
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-29
View more
  10 in total

1.  Mincle-binding DNA aptamer demonstrates therapeutic potential in a model of inflammatory bowel disease.

Authors:  Matthew Stephens; Keith Keane; Simon Roizes; Shan Liao; Pierre-Yves von der Weid
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-02       Impact factor: 10.183

Review 2.  Targeting TLR4-dependent inflammation in post-hemorrhagic brain injury.

Authors:  Jason K Karimy; Benjamin C Reeves; Kristopher T Kahle
Journal:  Expert Opin Ther Targets       Date:  2020-04-17       Impact factor: 6.902

Review 3.  TLR4-Targeting Therapeutics: Structural Basis and Computer-Aided Drug Discovery Approaches.

Authors:  Qurat Ul Ain; Maria Batool; Sangdun Choi
Journal:  Molecules       Date:  2020-01-31       Impact factor: 4.411

4.  New Mechanistic Insights, Novel Treatment Paradigms, and Clinical Progress in Cerebrovascular Diseases.

Authors:  Johannes Boltze; Jaroslaw A Aronowski; Jerome Badaut; Marion S Buckwalter; Mateo Caleo; Michael Chopp; Kunjan R Dave; Nadine Didwischus; Rick M Dijkhuizen; Thorsten R Doeppner; Jens P Dreier; Karim Fouad; Mathias Gelderblom; Karen Gertz; Dominika Golubczyk; Barbara A Gregson; Edith Hamel; Daniel F Hanley; Wolfgang Härtig; Friedhelm C Hummel; Maulana Ikhsan; Miroslaw Janowski; Jukka Jolkkonen; Saravanan S Karuppagounder; Richard F Keep; Inga K Koerte; Zaal Kokaia; Peiying Li; Fudong Liu; Ignacio Lizasoain; Peter Ludewig; Gerlinde A S Metz; Axel Montagne; Andre Obenaus; Alex Palumbo; Monica Pearl; Miguel Perez-Pinzon; Anna M Planas; Nikolaus Plesnila; Ami P Raval; Maria A Rueger; Lauren H Sansing; Farida Sohrabji; Charlotte J Stagg; R Anne Stetler; Ann M Stowe; Dandan Sun; Akihiko Taguchi; Mickael Tanter; Sabine U Vay; Raghu Vemuganti; Denis Vivien; Piotr Walczak; Jian Wang; Ye Xiong; Marietta Zille
Journal:  Front Aging Neurosci       Date:  2021-01-28       Impact factor: 5.750

5.  Role of Adaptor Protein Myeloid Differentiation 88 (MyD88) in Post-Subarachnoid Hemorrhage Inflammation: A Systematic Review.

Authors:  Hammad Ahmed; Mahtab Ahmad Khan; Ulf Dietrich Kahlert; Mika Niemelä; Daniel Hänggi; Shafqat Rasul Chaudhry; Sajjad Muhammad
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

6.  Role of TLR4 in Neutrophil Dynamics and Functions: Contribution to Stroke Pathophysiology.

Authors:  Violeta Durán-Laforet; Carolina Peña-Martínez; Alicia García-Culebras; María Isabel Cuartero; Eng H Lo; María Ángeles Moro; Ignacio Lizasoain
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

7.  First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers.

Authors:  Macarena Hernández-Jiménez; Samuel Martín-Vílchez; Dolores Ochoa; Gina Mejía-Abril; Manuel Román; Paola Camargo-Mamani; Sergio Luquero-Bueno; Bernd Jilma; María A Moro; Gerónimo Fernández; David Piñeiro; Marc Ribó; Víctor M González; Ignacio Lizasoain; Francisco Abad-Santos
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-09       Impact factor: 8.886

8.  [Expression of TLR4/MyD88/NF-κB pathway genes and its related inflammatory factors in secondary spinal cord injury].

Authors:  Shuang Mi; Yanjun Wu; Zhenghua Hong; Zhangfu Wang; Xingbing Feng; Guangbin Zheng
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-25

Review 9.  Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders.

Authors:  Rezan Ashayeri Ahmadabad; Zahra Mirzaasgari; Ali Gorji; Maryam Khaleghi Ghadiri
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

Review 10.  Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives.

Authors:  Carla Lucia Esposito; Silvia Catuogno; Gerolama Condorelli; Paola Ungaro; Vittorio de Franciscis
Journal:  Genes (Basel)       Date:  2018-10-31       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.